A randomized, double-blind, placebo-controlled single and multiple ascending dose study to test the safety, tolerability, pharmacokinetics and pharmacodynamics of NT-0167 in healthy volunteers
Latest Information Update: 26 Aug 2021
At a glance
- Drugs NT 0167 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man
- Sponsors Nodthera
Most Recent Events
- 03 Jul 2021 Status changed from not yet recruiting to discontinued.
- 09 Jun 2020 New trial record